Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective

18 Sept 2021

Abstract excerpt

Molecular targeted therapy has been reported to have fewer adverse effects, and offer a more convenient route of administration, compared with conventional chemotherapy. With the development of sequencing technology, and research on the molecular biology of lung cancer, especially whole-genome information on non-small cell lung cancer (NSCLC), various therapeutic targets have been unveiled. Among the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Treatments and Mutations
Share to Quinazolinone synthesis and applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34575576
DOI: 10.3390/pharmaceutics13091500

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and PerspectivePMID 34575576Read ↗

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

The next tier of EGFR resistance mutations in lung cancer.Semantic proximity Read ↗

Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical reviewSemantic proximity Read ↗

[Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].Semantic proximity Read ↗

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.Semantic proximity Read ↗

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].Semantic proximity Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC.Semantic proximity Read ↗

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.Semantic proximity Read ↗

[Application strategies of the third-generation EGFR-TKI in the context of precision medicine].Semantic proximity Read ↗

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.